Heart Failure Management with Beta Blockers

Introduction to Beta Blockers

The American Heart Association and American College of Cardiology recommend using carvedilol, metoprolol succinate, or bisoprolol for patients with heart failure with reduced ejection fraction (LVEF ≤40%) due to their proven mortality benefit 1
These three beta blockers have demonstrated mortality reduction in heart failure with reduced ejection fraction: carvedilol, metoprolol succinate (extended-release), and bisoprolol 1
The benefits of these beta blockers are seen across diverse populations, including women, elderly patients, and those with both ischemic and non-ischemic cardiomyopathy 1

Carvedilol has been found to have a 17% greater mortality reduction compared to immediate-release metoprolol tartrate in the COMET trial 2
Carvedilol blocks alpha-1, beta-1, and beta-2 receptors, has additional vasodilating properties, and may have more favorable effects on glycemic control compared to other beta blockers 2
Metoprolol succinate (extended-release) is beta-1 selective and has shown mortality benefit in heart failure, whereas metoprolol tartrate (immediate-release) performed worse than carvedilol in direct comparison 1

The recommended dosing for carvedilol is to start at 3.125 mg twice daily, with a target dose of 25-50 mg twice daily 4
The recommended dosing for metoprolol succinate (extended-release) is to start at 12.5-25 mg daily, with a target dose of 200 mg daily 4
The recommended dosing for bisoprolol is to start at 1.25 mg daily, with a target dose of 10 mg daily 4
It is recommended to start with low doses and titrate gradually (every 1-2 weeks if tolerated) 4

Patients should be monitored for worsening heart failure symptoms, hypotension, and bradycardia 4
Contraindications for beta blocker use include asthma, severe bronchial disease, symptomatic bradycardia, or hypotension 4
Patients with severe heart failure (NYHA Class III/IV), low blood pressure, or bradycardia should be referred for specialist care 4

The 2023 AHA/ACC Chronic Coronary Disease Guidelines state that beta-blocker therapy is not beneficial in reducing MACE in patients with CCD without previous MI or LVEF ≤50%, in the absence of another primary indication for beta-blocker therapy 3
Current evidence does not support using beta blockers as first-line therapy for uncomplicated hypertension 3